Altered methylation pattern of the SRD5A2 gene in cerebrospinal fluid of post-finasteride patients: a pilot study.

Recent findings in rat models confirmed that altered epigenetic processes, consisting in abnormal DNA methyltransferase protein levels and increased global DNA methylation levels, are linked to anxiety- and depression-like behaviour. Our finding of high levels of methylated SRD5A2 in CNS cells of a normotensive hydrocephalus individual, displaying an epigenetic status at odds with all other […]

Persistent sexual and nonsexual adverse effects of finasteride in younger men.

Conclusions: Persistent adverse effects of finasteride in younger men include erectile dysfunction, low libido, lack of orgasms, depression, and decreased alcohol consumption. One study has found lower levels of several neurosteroids in this population. Out of the various persistent side effects, erectile dysfunction and decreased alcohol consumption have been the most studied in animal models. […]

Sexual dysfunction in men taking systemic dermatologic medication: A systematic review.

Although there is some evidence against sexual dysfunction occurring in patients taking 5 mg and 10 mg of finasteride, most studies describe relatively common adverse effects of decreased libido, impotence, and ejaculation disorders… We identified 5 studies that did not support the increased rates of sexual dysfunction in men taking 1 mg finasteride for androgenic […]

Finasteride-Induced Inhibition of 5α-Reductase Type 2 Could Lead to Kidney Damage—Animal, Experimental Study.

Conclusions 1. The finasteride treatment of adult male rats led to a decrease in androgen receptor expression and its cellular translocation within the kidney cortex. 2. The pathomorphological changes (glomerulosclerosis, tubulosclerosis, dysplastic glomeruli, and tubules with lumen dilatation) in rats’ kidneys with disturbed steroid hormone imbalance were associated with the diminished expression of intracellular junctional […]

Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.

Conclusions: The risk of developing new onset type 2 diabetes appears to be higher in men with benign prostatic hyperplasia exposed to 5α-reductase inhibitors than in men receiving tamsulosin, but did not differ between men receiving dutasteride and those receiving finasteride. Additional monitoring might be required for men starting these drugs, particularly in those with […]

Finasteride is associated with a higher odds of obstructive sleep apnea (OSA): results from the US FDA Adverse Events Reporting System.

Finasteride, which crosses the blood-brain barrier, therefore lowers overall androgen activity. A decrease in androgen levels has been associated with [obstructive sleep apnea] and lower sleep efficiency in some studies. The odds of OSA with finasteride for any indication versus OSA with all other medication in FAERS used for any indication revealed…1,490 all other AE […]

Post-finasteride syndrome: a review of current literature.

The persistent symptoms reported by men after treatment of BPH or AGA with 5α-reductase inhibitors have been increasingly studied over the past decade. However, many of the studies investigated PFS using surveys of patients seeking treatment for PFS or from PFS-specific online forums, exposing the results to potential selection and recall bias. Further, there is […]

Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition.

Our findings indicate that finasteride treatment causes several alterations in the hippocampus that are detected at the end of the treatment… coincide with the apparition of depressive-like behavior, suggesting that long term effects of finasteride treatment on neurogenesis and neuroinflammation may participate in the enduring effects of the drug on depressive-like behavior, which are detected […]

The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption.

Finasteride treatment impairs biosynthesis and function of neurosteroids, which are critical regulators of central (CNS) as well as peripheral nervous system functions and modulate a host of neurotransmitter receptors, such as gamma amino butyric acid receptors. Thus, finasteride-induced neuroendocrine disruption of biosynthesis of critical signaling molecules results in pathophysiological states, which contribute to inhibition of […]

Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.

5a-RIs therapy, while improving urinary symptoms in patients with BPH and may prevent hair loss, produce significant adverse effects in some individuals including loss of libido, ED, ejaculatory dysfunction, and potential depression. They are serious enough to preclude them from pursuing such therapy…. The effects of these agents on vascular health should also be noted […]